Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2218 • ACR Convergence 2022
Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis
Namrata Singh¹, Laura Gold², Katherine Wysham³, James Andrews², Pankti Reid⁴, Una Makris⁵, Bryant England⁶, Jiha Lee⁷, Michael George⁸, Joshua Baker⁹, Jeffrey Jarvik², Patrick Heagerty² and Siddharth Singh¹⁰, ¹University of Washington, Bellevue, WA, ²University of Washington, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Chicago Medical Center, Chicago, IL, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ¹⁰University of California San Diego, San Diego
Background/Purpose: Recently, it has been recognized that frailty and pre-frailty are common in patients with rheumatoid arthritis (RA) [1]. Whether frailty status portends an increased…
Abstract Number: PP18 • ACR Convergence 2022
From Devastated to Empowered: How Patient Engagement in Research Changes Lives
Eileen Davidson, Burnaby, BC, Canada
Background/Purpose: In April of 2015 I was a 29 year-old single mom diagnosed with rheumatoid arthritis (RA). RA wasn't unknown to me; my aunt who…
Abstract Number: 0047 • ACR Convergence 2022
Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis
Thomas Hoyler, Jeremy Scherer, Maxime Bulle, Conrad Wyss, Sylvie Froidevaux and Marianne Martinic, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Targeting the sphingosine-1-phosphate (S1P) pathway has become an attractive target for therapeutic intervention in autoimmune diseases due to its selective impact on the migration…
Abstract Number: 0086 • ACR Convergence 2022
Patient and Provider Perspectives on Barriers to Communication and Care of Latinx Patients with Lupus and Rheumatoid Arthritis
Monica Crespo Bosque¹, Pablo Weilg Espejo² and Candace Feldman³, ¹Boston University, Boston, MA, ²Boston Medical Center, Chelsea, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Latinx patients, a heterogenous population with a range of experiences including migration, language, and race, experience a disproportionate burden of adverse outcomes from systemic…
Abstract Number: 0203 • ACR Convergence 2022
Feasibility and Acceptability of Integrating Patient Reported Outcomes Within Routine Care of Rheumatoid Arthritis
Manisha Verma¹, Pragya Singh², MICHAEL KEITH², LYNN GERBER², ROBERT CHAO², ERICA MCBRIDE², Yingxue Zhang², Manirath Srishord² and ZOBAIR YOUNOSSI², ¹Inova Health System, Wynnewood, PA, ²Inova Health System, Falls Church, VA
Background/Purpose: Advancements in measurement science have demonstrated that patient reported outcomes (PROs) can act as supplements to clinical markers for a comprehensive assessment of disease…
Abstract Number: 0252 • ACR Convergence 2022
Mitochondrial Content in Skeletal Muscle of Individuals with Rheumatoid Arthritis Is Associated with Physical Activity Level
Beatriz Hanaoka¹, Jason Benedict¹, Guy Brock¹, Jillian Johnson¹, Peter Reiser¹, Kelley Smith-Johnston², Melissa Sammy³ and Douglas Moellering³, ¹The Ohio State University, Columbus, OH, ²University of Alabama at Birmingham, Birmigham, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with a high prevalence of insulin resistance. Skeletal muscle is the major contributor to peripheral…
Abstract Number: 0268 • ACR Convergence 2022
Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry
Ching-Tsai Lin¹, Wen-Nan Huang¹, Yi-Hsin Chen² and Yi-Ming Chen³, ¹Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ²Taichung Veterans General Hospital, Taichung, Taiwan, ³Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Patients with rheumatoid arthritis (RA) were associated with increased mortality rate. Our study aimed to investigate the risk factors associated with all causes of…
Abstract Number: 0286 • ACR Convergence 2022
Efficacy and Safety of Upadacitinib in Patients Across Races with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3 Clinical Trials
Grace Wright¹, Eduardo Mysler², Iris Navarro-Millan³, Yoshiya Tanaka⁴, Samuel Anyanwu⁵, Jianzhong Liu⁵, Oishi Tanjinatus⁵, Andrew Garrison⁵ and Alvin Wells⁶, ¹Association of Women in Rheumatology, New York, NY, ²Department of Rheumatology, OMI (Medical Research Organization), Buenos Aires, Argentina, ³Weill Cornell Medicine, New York, NY, ⁴University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁵AbbVie, Inc., North Chicago, IL, ⁶Aurora Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: RA affects diverse patient populations with varying disease severity and treatment responses. However, data on treatment response to advanced therapies by race are limited.1…
Abstract Number: 0302 • ACR Convergence 2022
Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
SE RIM CHOI¹, Anna Shin², You-Jung Ha², Yun Jong Lee², Eun Bong Lee¹ and Eun Ha Kang², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Background/Purpose: To compare infectious risk between JAK inhibitors (JAKi) versus TNF inhibitors (TNFi) among patients with rheumatoid arthritis (RA) in Korea. Methods: Using 2009-2019 Korea…
Abstract Number: 0500 • ACR Convergence 2022
T Cell and Macrophage Synergy Drive Inflammatory Synovial Fibroblasts in Rheumatoid but Not Psoriatic Arthritis
Achilleas Floudas¹, conor Smith², Orla Tynan³, Nuno Neto⁴, Krishna Vinod⁵, Sarah Wade⁶, Megan Hanlon⁷, Clare Cunningham⁴, Viviana Marzaioli⁸, Mary Canavan⁹, Jean Fletcher³, Ronan Mullan¹⁰, Suzanne Cole¹¹, Ling-Yang Hao¹², Michael Monaghan⁴, Sunil Nagpal¹³, Douglas Veale¹⁴ and Ursula Fearon⁴, ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ²bTrinity College Dublin, Dublin, Ireland, ³Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Janssen, Spring House, PA, ⁶Trinity Biomedical Sciences Institute, Wexford, Ireland, ⁷Molecular Rheumatology, Dublin, Ireland, ⁸Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁹Trinity College, Dublin, Ireland, ¹⁰Tallaght University Hospital, Dublin, Ireland, ¹¹Rheumatic Disease Associates, Warminster, PA, ¹²Janssen Research and Development, LLC, Spring House, PA, ¹³Janssen Research, Collegeville, PA, ¹⁴St. Vincent's University Hospital, Blackrock, Dublin, Ireland
Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are common autoimmune diseases of unknown aetiology characterised by complex synovial pathology with a detrimental effect on the…
Abstract Number: 0573 • ACR Convergence 2022
Telehealth versus Outpatients Clinic Follow up in Rheumatoid Arthritis Patients a Randomized Controlled Study
Anne Bull Haaversen¹, Inge Christoffer Olsen², Maiju Pesonen³, Andreas Diamantopoulos⁴ and jannicke Sundsby karlengen⁵, ¹Martina Hansens Hospital, Hosle, Norway, ²Oslo University Hospital, Oslo, Nepal, ³Oslo University, Oslo, Norway, ⁴Akershus University Hospital, Lørenskog, Norway, ⁵Martina Hansens Hospital, Baerum, Norway
Background/Purpose: Most Rheumatoid Arthritis (RA) patients are in remission or low disease activity. Yet, RA patients continue to be followed up by pre-scheduled visits, which…
Abstract Number: 0600 • ACR Convergence 2022
Correlates Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Phenotypes: Data from the Accelerated Medicines Partnership
Dana Weisenfeld¹, Fan Zhang², Laura Donlin³, Anna Jonsson¹, William Apruzzese¹, Debbie Campbell⁴, Ellen Gravallese⁵, Larry Moreland⁶, Susan Goodman³, Michael Brenner⁵, Soumya Raychaudhuri¹, Andrew Filer⁷, Jennifer Anolik⁸, Vivian Bykerk³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Aurora, CO, ³Hospital for Special Surgery, New York, NY, ⁴University of Rochester, Rochester, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶University of Colorado, Denver, CO, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University of Rochester Medical Center, Rochester, NY
Background/Purpose: Prior studies have characterized the diverse cell types in the RA synovium through a multi-center consortium incorporating RNA-seq data. Due to the novelty of…
Abstract Number: 0618 • ACR Convergence 2022
Regulation of IgA Secretion Through PAD2-mediated Citrullination of MZB1
Bo Sun¹, Benjamin Geary², Santanu Mondal³, Ronak Tilvawala⁴, Konstantin Tsoyi⁵, Ivan O. Rosas⁵, Paul Thompson³ and I-Cheng Ho², ¹Brigham and Women's Hospital, Lexington, MA, ²Brigham and Women's Hospital, Boston, MA, ³UMass Medical School, Worcester, MA, ⁴University of Kansas, Lawrence, KS, ⁵Baylor College of Medicine, Houston, TX
Background/Purpose: The secretion of antibody requires concerted action of several endoplasmic reticulum proteins (ERPs) in B cells. For example, marginal zone B and B1 cell-specific…
Abstract Number: 0719 • ACR Convergence 2022
Effect of Patient-reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
Lauren Stevens¹, Kyra Mulder², Zhaohui Su², Pam Kumparatana², Jessica Paulus² and Stefan Weiss³, ¹OM1, Inc., Lexington, KY, ²OM1, Inc., Boston, MA, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: Patient-reported outcomes (PROs) are being increasingly utilized in clinical trials to assess the impact of treatment on symptom control and patient quality of life.…
Abstract Number: 0783 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases
Md Yuzaiful Md Yusof¹, Jack Arnold², Benazir Saleem³, Claire Vandevelde³, Shouvik Dass³, Sinisa Savic¹, Edward M Vital¹ and Paul Emery¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³Rheumatology Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: There are concerns regarding the safety of rituximab (RTX) during the COVID-19 pandemic due its effect on humoral immunity. Data from registries during pre-vaccination…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].